tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
PremiumRatingsPromising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
25d ago
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
Premium
Ratings
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
25d ago
Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
Premium
Ratings
Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
26d ago
Cytokinetics Faces Lawsuit Over Misleading Investors
PremiumClass ActionCytokinetics Faces Lawsuit Over Misleading Investors
1M ago
Morning Movers: Workday surges after Elliot stake, stock buyback program
Premium
The Fly
Morning Movers: Workday surges after Elliot stake, stock buyback program
1M ago
Cautious Outlook on Cytokinetics: Hold Rating Amid Competitive Challenges and Uncertain Commercial Impact
Premium
Ratings
Cautious Outlook on Cytokinetics: Hold Rating Amid Competitive Challenges and Uncertain Commercial Impact
1M ago
Cytokinetics price target raised to $52 from $45 at BofA
PremiumThe FlyCytokinetics price target raised to $52 from $45 at BofA
2M ago
Buy Rating Justified for Cytokinetics Due to Aficamten’s Advantages in HCM Treatment
Premium
Ratings
Buy Rating Justified for Cytokinetics Due to Aficamten’s Advantages in HCM Treatment
2M ago
Cytokinetics price target raised to $80 from $60 at Evercore ISI
Premium
The Fly
Cytokinetics price target raised to $80 from $60 at Evercore ISI
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100